Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for

Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer is a phase 2, interventional study registered as NCT06872606 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 33 participants, started 2025-04-01 and due to reach its primary completion in 2026-04-01. Interventions recorded: Pucotenlimab; Bevacizumab; Oxaliplatin; Trifluridine/Tipiracil Hydrochloride; Short-course radiotherapy; intracavitary brachytherapy. Conditions listed: Rectal Adenocarcinoma. Primary outcome: Organ preservation rate. Colorectal eligibility wording from the registry: "Diagnosed by digital rectal examination, colonoscopy, and high-resolution MRI of the pelvis, the tumor is less than or equal to 5 cm from the anus". Sites: China. No results are recorded here; the registry entry is the source.